Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1386]

First randomised evidence for benefit from adding a tyrosine kinase inhibitor...

Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany

First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia ( Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany )

Chemo-free treatment approach demonstrates positive responses in leukaemia...

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

Chemo-free treatment approach demonstrates positive responses in leukaemia patients ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )

Compound improves survival in aggressive acute myeloid leukaemia with...

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )

Nivolumab shows early promise in Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA

Nivolumab shows early promise in Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )

Blinatumomab demonstrates significant clinical activity in residual ALL

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

Blinatumomab demonstrates significant clinical activity in residual ALL ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

New immunotherapy compound effective, safe in ALL patients with minimal...

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

New immunotherapy compound effective, safe in ALL patients with minimal residual disease ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

T cell therapy leading to prolonged remission for children with aggressive...

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

T cell therapy leading to prolonged remission for children with aggressive leukaemia ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

ASH 2014: Expert discussion on the latest in AML

Prof Alan Burnett and Prof Sergio Amadori

ASH 2014: Expert discussion on the latest in AML ( Prof Alan Burnett and Prof Sergio Amadori )

ASH 2014: Expert discussion on the latest in CLL

Prof John Gribben and Prof Stephan Stilgenbauer

ASH 2014: Expert discussion on the latest in CLL ( Prof John Gribben and Prof Stephan Stilgenbauer )

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive...

Dr Thomas Martin, MD, University of California, San Francisco, USA

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma ( Dr Thomas Martin, MD, University of California, San Francisco, USA )

More from ecancer